I-Mab News

(IMAB) - Analyzing I-MAB's Short Interest

I-MAB's (NYSE:IMAB) short percent of float has risen 113.98% since its last report. The company recently reported that it has 1.30 million shares sold short, which is 3.98% of all regular shares that

BenzingaMay 7 14:45 ET

Patent Law Changes Pose Threat to I-Mab Adr's Drug Candidate Protection

TipRanksMay 1 02:02 ET

I-MAB Filed 2023 Annual Report on Form 20-F

ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hig

I-Mab BiopharmaApr 30 00:00 ET

Verastem Names John Hayslip as Chief Medical Officer

Verastem (VSTM) said late Thursday it appointed John Hayslip as chief medical officer, succeeding Louis Denis, who recently left the company. Hayslip most recently served as the chief medical officer

MT NewswiresApr 18 17:36 ET

I-Mab Announces CMO Transition, Interim Successor Named

TipRanksApr 15 21:03 ET

I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline

TipRanksApr 12 06:08 ET

Express News | Needham Reiterates Buy on I-MAB, Maintains $6 Price Target

Moomoo 24/7Apr 12 06:04 ET

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiate

I-Mab BiopharmaApr 5 00:00 ET

I-Mab Finalizes Divestiture and Resolves Obligations

TipRanksApr 2 17:59 ET

I-Mab Transferred I-Mab Biopharma (Shanghai) to I-Mab Biopharma (Hangzhou) for Up to $80M >IMAB

I-Mab Transferred I-Mab Biopharma (Shanghai) to I-Mab Biopharma (Hangzhou) for Up to $80M >IMAB

Dow JonesApr 2 16:02 ET

I-Mab Closes Divestiture of Business Ops in China >IMAB

I-Mab Closes Divestiture of Business Ops in China >IMAB

Dow JonesApr 2 16:01 ET

I-Mab Announces Major Leadership Reshuffle

TipRanksApr 1 09:57 ET

NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Sec

BenzingaMar 18 07:52 ET

I-Mab Price Target Cut to $10.00/Share From $15.00 by Piper Sandler

I-Mab Price Target Cut to $10.00/Share From $15.00 by Piper Sandler

Dow JonesMar 18 07:27 ET

I-Mab Is Maintained at Overweight by Piper Sandler

I-Mab Is Maintained at Overweight by Piper Sandler

Dow JonesMar 18 07:27 ET

Express News | Piper Sandler Maintains Overweight on I-MAB, Lowers Price Target to $10

Moomoo 24/7Mar 18 07:16 ET

Express News | HC Wainwright & Co. Reiterates Buy on I-MAB, Lowers Price Target to $8

Moomoo 24/7Mar 18 06:41 ET

Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)

TipRanksMar 18 06:20 ET

Express News | Needham Maintains Buy on I-MAB, Lowers Price Target to $6

Moomoo 24/7Mar 15 09:28 ET

I-MAB: A Strong Buy on Strategic U.S. Focus and Promising Oncology Pipeline

TipRanksMar 15 07:46 ET